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Introduction: β-adrenergic system is altered in heart failure (HF) due to
non-ischemic dilated cardiomyopathy (DCM). There are few data concerning
the relative contribution of β1- and β3-adrenoceptor subtypes (β1- and β3-AR)
during DCM development. We evaluated the expression and the role of each
β-AR subtype in this pathology.
Methods: DCM rat model is performed by doxorubicin injections (cumu-
lative dose: 15 mg.kg-1) and validated by in vivo measurements with echocar-
diography-doppler. The variations of β1- and β3-AR transcript expression in
left ventricle (LV) are evaluated by real-time RT-PCR. The ex vivo cardiac
responses induced by selective β3-AR or non-selective β-AR stimulations are
evaluated on isolated perfused heart.
Results: DCM rats present LV dilation, systolic and diastolic dysfunction
(see table). Compared to controls, β1-AR transcripts and β3-AR transcripts are
increased in DCM LV (+36%, n=8, p<0.05 and +358 %, n=8, p<0.05). Ex vivo
parameters are summarized in the table.
Conclusion: DCM induces a β3-AR gene over-expression, associated to an
increase of β3AR-induced negative inotropic and lusitropic effects. Those
results could partly explain the alteration of isoproterenol response in our
model, suggesting that β3-AR could be a new therapeutic target in DCM.
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Background: Although estrogen administration to hysterectomized meno-
pausal women did not prevent the occurence of myocardial infarction in a ran-
domized controlled trial (WHI 2004), epidemiological studies suggest and
experimental results clearly demonstrate a major atheroprotective action of
estrogens. The goal of the present study was to identify the cellular target(s)
accounting for the estradiol (E2) beneficial action on fatty streak development.
Methods and Results: We first confirmed the key role of estrogen receptor
α (ERα) in atheroprotective effect of E2 as this action was completely abolished
in mice deficient both in Low Density Lipoprotein receptor (LDLr) and in ERα.
Comparison of LDLr–/– mice transplanted with either ERα+/+ or ERα–/– bone
marrow showed that functional ERα in the hematopoietic lineage is not required
for E2 atheroprotection. We then showed that ERα floxed mice (ER_flox/flox)
bred with the Tie2-Cre mice on the LDLr–/–- background had a complete inac-
tivation of ERα both in bone marrow and in endothelial cells. Remarkably, in
this mouse model, the E2 atheroprotective action was completely abolished.
Conclusions: Altogether, this is the first in vivo demonstration that endot-
helial ERα represents a key target of the atheroprotective effect of E2, whereas
the hematopoietic ERα isdispensable for the protective action. Selective
estrogen receptor modulators that mimic this endothelial action of E2 should
now be considered in hormonal treatment as well as in atheroprotection.
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Objectives: Although reducing rates of restenosis, drug-eluting stents also
impair endothelial healing, resulting in increased risk of thrombosis. Alterna-
tively, inhibition of neointimal hyperplasia is favoured by acceleration of reen-
dothelialization. We previously showed that E2 accelerates reendothelialization
through Estrogen Receptor α (ERα) and we now aimed at defining the cellular
targets of this action.
Methods and Results: The respective roles of endothelial and hematopoi-
etic cellular targets of E2 were investigated in a mouse carotid injury model,
using “en face” confocal microscopy, to follow endothelium repair. Grafting
ERα –/– mice with ERα +/+ bone marrow (BM) did not restore the accelera-
tive effect of E2 on reendothelialization, demonstrating the necessary role of
extrahematopoietic ERα. Using a cell-specific inactivation of ERα (Cre-lox
recombination system), we showed that endothelial ER_ plays a pivotal role in
the E2 action. Finally, in wild type mice grafted with ERα –/–, the regenera-
tive effect of E2 was abolished, demonstrating that ERα-expressing hemato-
poietic cells are also concomitantly required.
Conclusions: We demonstrate that endothelial ERα plays a pivotal role in
E2-mediated reendothelialization. However, endothelial targeting alone is not
sufficient and the concomitant stimulation of BM ERα is absolutely required.
This cooperation should be now taken into account in strategies aimed at opti-
mizing in-stent reendothelialization.
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Ischemic preconditioning and postconditioning are two effective thera-
peutic strategies for reducing infarct size in animal models and humans. The
aim of our study was to compare the early regulated genes of preconditioning
and postconditioning using a transcriptomic approach.
Methods: C57Bl6, Zac1+/– KO (n=7) and WT littermates (n=4) mice
underwent an IR (40 min. ischemia/60 min.reperfusion) protocol. C57Bl6
mice were randomly assigned to different groups: IR (n=22); postconditioning
(PostC, n=21): a protocol of 3 cycles of 1-minute reperfusion and 1-minute
reocclusion was applied at the onset of reperfusion; preconditioning (PreC,
n=15; same algorithm but applied before ischemia. At the end of surgery, left
ventricles were assigned to RNA extraction or infarct size assessment. Home-
made mouse oligo microarrays were used for gene expression profiling (Mont-
pellier GenomiX Facilities). Determination of area at risk (AR) and infarct size
was assessed by TTC staining and planimetry.
Results: Our study revealed that despite a similar cardioprotection offered
by PreC and PostC on infarct size, PostC regulates a larger number of genes
compared to PreC (242 versus 40). Only 8 genes were jointly regulated by
PreC and PostC and considered as putative cardioprotective key regulators.
Among these candidates, Zac1 was down regulated at the transcriptional levels
upon PreC and PostC. Moreover, infarct size/AR was 29%-decreased in Zac1
+/– KO mice subjected to a surgical protocol of myocardial IR.
Table: Basal parameters and maximum values obtained by non-selective 
β1-AR stimulation (isoproterenol) or selective β3-AR stimulation 
(SR58611A). Results are expressed by mean ± SEM.*: p<0.001 vs Control, 
£: p<0.001 vs Basal.
   Control rats 
(n=9-31)
DCM rats 
(n=10-31)
Basal 
in vivo  
 LV end-diastolic diameter (mm)  8.82±0.33 7.61±0.17 * 
 LV ejection fraction (%)  83.0±1.9 71.2±2.8* 
 LV Isovolumic relaxation 
time (ms)  21.41±1.13 32.39±1.10* 
Basal ex vivo
 DP/dt max (mmHg.s-1)  2035±365  2669±504*
 DP/dt min (mmHg.s-1)  –1258±226  –1847±349*
Isoproterenol 
ex vivo (1 μM)
 DP/dt max (mmHg.s-1)  5263±1754 4373±1383*
 DP/dt min (mmHg.s-1)  –3815±1271 –3227±1020*
SR58611A 
ex vivo (1 μM) 
 DP/dt max (mmHg.s-1) 1722±497  1930±611£
 DP/dt min (mmHg.s-1)  –1027±297 –1138±360£
